SARS-CoV-2 (COVID-19) Morbidity and Chronic Disease (Type II Diabetes –T2D) and Pancreatic Carcinoma: Clinco-epidemiologic Perspective
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Holmes, LaurensDeepika, Kerti
Williams, Janille
Ogundele, Benjamin
Philipcien, Glen
Enwere, Michael
Jain, Shikha
Dasari, Naresh
Alur, Ram
Adhikari, Ramesh
Ogungbade, Gbadebo
Journal title
Medical Research ArchivesDate Published
2022-06-20Publication Volume
10Publication Issue
6
Metadata
Show full item recordAbstract
Purpose: Viral infections had been historically observed in chronic disease development and complications including although not limited to hepatitis C, influenza A, cytomegalovirus (CMV), Epstein bar virus (EBV), HIV and herpes simplex. Epidemiologic data had implicated CMV, herpes simplex and hepatitis C in type II diabetes (T2D). With the observed increased incidence T2D in COVID-19 among children and adults, this review aimed to examine scientific literature on immune and endocrine systems dysregulation in T2D and pancreatic neoplasm. Materials & Method: A qualitative systematic review (QSR) was utilized in assessing the immune system deregulation and endocrine system involvement in chronic disease development such as T2D. The PubMed was the main search engine in studies identification with several search terms such as “SARS-CoV-2 and T2D”, “COVID-19 and T2D”, SARS-CoV-2 and insulin resistant”, etc. Results: Viral pathogens such as CMV, influenza A, and herpes simplex and hepatitis C infections have been implicated in decreased insulin sensitivity (IS) and increased insulin resistant (IR). Similarly, these pathogenic microbes increased the T2D incidence and complications. SARS-CoV-2 a COVID-19 causative pathogen had been observed in increased risk and incidence of T2D among children and adults. While data are not currently available on the precise mechanistic process, SARS-CoV-2 viral infection in T2D incidence may be explained by excess pro-inflammatory cytokines elaboration (cytokine storm) resulting in increased IR and decreased IS, leading to glucose intolerance and T2D. Further COVID-19 may increase pancreatic neoplasm in populations with increased incidence of COVID-19, due to pancreatic beta cells and insulin receptors dysregulation and cellular dysfunctionality as abnormal cellular proliferation. Conclusions/Recommendation: SARS-CoV-2 a causative pathogen in COVID-19 morbidity is associated with increased incidence of T2D, which is explained in part by immune and endocrine system integration dysregulation, resulting in cytokine storm, decreased IS and increased IR, implying glucose intolerance and T2D. Additionally this pathogenic microbe may result in increasing incidence of pancreatic neoplasm, a malignant neoplasm with the worst prognosis and excess mortality due to late stage at diagnosis and marginalized biomarkers of susceptibility and morbidity.Citation
HOLMES, JR, Laurens et al. SARS-CoV-2 (COVID-19) Morbidity and Chronic Disease (Type II Diabetes –T2D) and Pancreatic Carcinoma: Clinco-epidemiologic Perspective. Medical Research Archives, [S.l.], v. 10, n. 6, june 2022. ISSN 2375-1924. doi: https://doi.org/10.18103/mra.v10i6.2785.DOI
10.18103/mra.v10i6.2785ae974a485f413a2113503eed53cd6c53
10.18103/mra.v10i6.2785
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International